Key result
Intravenous administration of TAK-242-NP at reperfusion decreased infarct size in a mouse model of myocardial ischaemia-reperfusion injury, whereas TAK-242 solution did not.
Why the study?
Blockade of Toll-like receptor 4 in myocardial ischaemia-reperfusion injury has not been translated into clinical practice.
Does intravenous TAK-242-NP reduce infarct size in a mouse model of myocardial ischaemia-reperfusion injury?
Does intravenous TAK-242-NP reduce infarct size in a mouse model of myocardial ischaemia-reperfusion injury?
Nanoparticle-mediated delivery of the TLR4 inhibitor TAK-242 reduces myocardial infarct size in a mouse model of ischaemia-reperfusion injury by inhibiting monocyte-mediated inflammation.
No takes yet. Share an insight, caveat, or question.
TAK-242-NP reduces infarct size at reperfusion in mice where free drug fails; leaves open translation to clinical ischaemia-reperfusion injury.
Fujiwara et al. (2019) studied Myocardial ischaemia-reperfusion injury. TAK-242-NP (nanoparticle-mediated administration of TAK-242) vs. TAK-242 solution was evaluated on Infarct size. Intravenous administration of TAK-242-NP at reperfusion decreased infarct size in a mouse model of myocardial ischaemia-reperfusion injury, whereas TAK-242 solution did not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: